
X
Chasing Brilinta payoff, AZ details THALES data in ischemic stroke
https://pharmaphorum.com/news/chasing-brilinta-payoff-az-details-thales-data-in-ischemic-stroke/
A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients.
Brilinta will not hit $3.5bn sales target, company admits.
Recommendation will add to growth trajectory